TriangleNCT01822886 · REGISTRY CONDITION SEARCH
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2019-10-14
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Complete Remission (CR) Rate
Percentage of Participants With Progression-Free Survival
Overall Survival is Measured From the Date of Study Entry to the Date of Patient's Death
Safety - Frequency of Toxicities Grade 3 and 4
Overall Response Rate (ORR)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients with histological diagnosis of PTCL according to the WHO (World Health Organization) classification * Age ≥ 18 years * Relapsed (≥1) or refractory to conventional chemotherapy/radiotherapy * Stage I-IV according to the Ann Arbor staging System * ECOG (Eastern Cooperative Oncology Group) Performance status ≤2 * Normal renal and hepatic functions * Laboratory test results as follows: * Serum creatinine ≥ 2.0 mg/dL * Total bilirubin ≥ 1.5 mg/dL * AST (SGOT) and ALT (SGPT) £2 x ULN or £5 x ULN if hepatic metastases are present * Negative HIV HCV and HBV status * Adequate bone marrow reserve: Platelet count\>100X109 cells/L or platelet count \<75X109 cells/L if bone marrow disease involvement, absolute neutrophile count (ANC)\> 1,5 X109, hemoglobin\>8 g/dl. * Able to adhere to the study visit schedule and other protocol requirements * Cardiac ejection fraction (MUGA scan or echocardiography) \> 45% * Life expectancy \> 6 months * Females of childbearing potential (FCBP) must have a negative serum or urine β-hCG pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy * Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days after the last dose of study drug. * Measurable disease of at least 2 cm as detected by CT scan, assessed by site radiologist * Patients or they legally authorized representative must provide written informed consent Exclusion Criteria: * Any serious active disease or co-morbid medical condition (according to investigator's decision) * Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form * Patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation * Corrected QT interval \> 480 msec (using the Fridericia formula) * Low K+ (\<3.8 mmol/L) and low Mg+ (\<0.85 mmol/L) levels, except if corrected before beginning the chemotherapy * Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study * Previous exposure to romidepsin or gemcitabine * CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement * History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances * Active opportunistic infection
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
- intervention Names
- Drug: Romidepsin + Gemcitabine
- label
- Romidepsin, Gemcitabine
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Romidepsin, Gemcitabine
- description
- Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
- name
- Romidepsin + Gemcitabine
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 20
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Complete Remission is disappearance of all target lesions per the Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007)"
- measure
- Complete Remission (CR) Rate
- time Frame
- 18 months
- secondary Outcomes
- description
- The time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS (progression-free survival) data will be censored on the day following the date of the last radiological assessment of measured lesions documenting absence of progressive disease for patients who do not have objective tumor progression and are still on study at the time of an analysis, are given antitumor treatment other than the study treatment or stem cell transplant, or are removed from study prior to documentation of objective tumor progression. Patients lacking an evaluation of tumor response after their first dose will have their event time censored at 1 day. Percentage of participants is an estimate based on Kaplan-Meier method.
- measure
- Percentage of Participants With Progression-Free Survival
- time Frame
- 24 months
- description
- OS (overall survival) is measured from the date of study entry to the date of patient's death. If the patient is alive or his vital status is unknown, the date of death will be censored at the date that the patient is last known to be alive.
- measure
- Overall Survival is Measured From the Date of Study Entry to the Date of Patient's Death
- time Frame
- 24 months
- description
- Frequency of toxicities was reported by type and grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
- measure
- Safety - Frequency of Toxicities Grade 3 and 4
- time Frame
- 24 months
- description
- ORR the proportion of patients who achieve CR (complete response), CRu (complete remission unconfirmed) or PR (partial response) relative to the per-protocol population. Disease response and progression will be evaluated according to the "Revised Response Criteria" for malignant lymphoma (Cheson et al. 2007).
- measure
- Overall Response Rate (ORR)
- time Frame
- 24 months
Full study description
- brief Summary
- Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.
- detailed Description
- Objectives will be focused on preliminary dose-response, type of patients, frequency of dosing, and safety and tolerability profile.
Source references
- references
- citation
- Pellegrini C, Dodero A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P, Zinzani PL; Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL). A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. J Hematol Oncol. 2016 Apr 12;9:38. doi: 10.1186/s13045-016-0266-1.
- pmid
- 27071522
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-324f99f645082414ca28
- requested nct id
- NCT01822886
- primary nct id
- NCT01822886
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- payload sha256
- 0faa28af46cd469b391705e8893abe8b7767b6e1b89032103f81aaee158458d9
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-324f99f645082414ca28
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01822886
- occurrences
- context exact
- NCT01822886
- end
- 11
- exact text
- NCT01822886
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Peripheral T-Cell Non-Hodgkin Lymphoma
- query disease state id
- ds-peripheral-t-cell-non-hodgkin-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- source json pointer
- /studies/114/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 686fd12b35307e144678780ce774ac2979070bfb7858eb4569c443c761196c5d
Preserved source evidence · Not medical advice